Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK2 | Q16620 | 2/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.56 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | PRKACA | P17612 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.55 |
| ▸ | MST1R | Q04912 | 1/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.55 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997 | 0.90 | PRF1 (0.50) | NTRK2CLK4DYRK1BTYRO3JAK2 | |
| SCHEMBL8723086 | 0.73 | CLK4 (1.00) | NTRK2CLK4DYRK1BTYRO3JAK2 | |
| SCHEMBL11575 | 0.72 | CLK4 (0.53) | NTRK2CLK4DYRK1BTYRO3JAK2 | |
| SCHEMBL31037780 | 0.72 | NTRK2 (0.49) | NTRK2CLK4DYRK1BTYRO3JAK2 | |
| SCHEMBL4728825 | 0.72 | NTRK2 (0.45) | NTRK2CLK4DYRK1BTYRO3JAK2 | |
| SCHEMBL4730231 | 0.71 | NTRK2 (0.44) | NTRK2CLK4DYRK1BTYRO3JAK2 | |
| SCHEMBL30775346 | 0.71 | CLK4 (0.73) | NTRK2CLK4DYRK1BTYRO3JAK2 | |
| SCHEMBL21731307 | 0.71 | CLK4 (0.73) | NTRK2CLK4DYRK1BTYRO3JAK2 | |
| SCHEMBL29985572 | 0.71 | CLK4 (0.74) | NTRK2CLK4DYRK1BTYRO3JAK2 | |
| SCHEMBL19187116 | 0.71 | CLK4 (0.74) | NTRK2CLK4DYRK1BTYRO3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2488489-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HAX1, LPXN, AGXT | NTRK2 4633/4885CLK4 3296/4885DYRK1B 3582/4885 |
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LCT, AGXT, PRXL2A | NTRK2 4794/4885CLK4 2560/4885DYRK1B 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.